Ejaculation Problems: Too Fast, Too Slow or Not at All?

Penile biothesiometry studies have shown that patients with PE have increased penile sensitivity

MeSH terms

Furthermore, the WHO definition excludes men whose PE is predominately attributed to (i) alcohol, substance abuse, and/or medications; (ii) a sexual context that has led to very high levels of arousal because of the novelty of partner or situation; and (iii) a low frequency of sexual activity [1]. Others have based their diagnosis on the number of penile thrusts occurring before ejaculation, considering less than 8–15 thrusts as the criterion for PE [2,3]. In 2007, responding to the variability of worldwide definitions and the need for a universal standard, the International Society for Sexual Medicine (ISSM) established an ad hoc committee consisting of 21 internationally recognized experts, to establish a new definition of PE. This latest ISSM definition, based on the recommendations of the most active and respected clinical and basic science experts in the field, characterized PE as follows: “Premature ejaculation is a male sexual dysfunction characterized by ejaculation which always or nearly always occurs prior to or within about one minute of vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal penetrations; and negative personal consequences, such as distress, bother, frustration and/or the avoidance of sexual intimacy” [4]. Based on this new definition, some investigators may question the conclusions of previous studies with potentially inadequate patient selection definitions.

Low blood pressure

Other related definitions include primary or lifelong PE—presence of the problem from the onset of initial sexual activity; acquired or late onset PE—indicates that the problem has developed after an initial time of unimpaired ejaculatory function; and situational (vs. global) PE—indicates PE that is limited to specific partner or situation, while the patient enjoys satisfactory intercourse in other contexts [5]. The National Health and Social Life Survey, a probability sample study of sexual behavior in men and women aged 18–59 years, reported a prevalence of 21% among men in the United States [6]. Nathan [7] analyzed the findings of 22 general population sex surveys, and estimated the prevalence of PE to be 35%. Most estimates from other general population prevalence studies fall between buy sildenafil citrate online canada 22% and 38%, with ranges from 4% to 39% [8–10].

Conservative Non-surgical Options for Erectile Dysfunction

The wide variability in the reported ranges is mirrored in the variability and lack of standardized definitions for PE. A number of studies have raised the point that in spite of the high prevalence rates, PE is the disorder for which patients are least likely to seek professional assistance, raising the distinct possibility that the problem may be more prevalent than currently estimated [8,10]. More recently, the PE Prevalence and Attitudes (PEPA) internetbased survey of 12,133 men aged 18–70 in the United States, Germany, and Italy reported a prevalence of 22.7% [11]. It is noteworthy that only 9% of the men in this survey had consulted a physician, and more than 90% reported little or no improvement after they sought treatment, leading to a general lack of satisfaction with the results. It has also been suggested that the prevalence of PE may vary between racial groups; one recent survey of 1,320 men found that PE was more prevalently admitted among Hispanic men, highlighting the importance of further investigation of ethnic and cultural variances in PE worldwide [12]. as shown by consistently decreased vibratory threshold that is not age dependent [24,25].

Parameter	Data	Notes
Tolerance development	Rare, possible with prolonged use	Monitoring advised
Dependency risk	Low	Not considered addictive
Long-term side effects	Unclear, ongoing research	Regular medical check-ups recommended
Impact on cardiovascular health	Generally safe in healthy individuals	Caution in pre-existing cardiovascular conditions

Lidocaine- or prilocaine-based sprays, creams, or gels, as well

Product	Dosage	Quantity + Bonus	Price
Viagra Generic	25mg	20 Pills	37.74€ 35.94€	Buy
Kamagra Polo	100mg	180 + 8 Pills	446.52€ 425.26€	Buy
Kamagra Soft Tabs	100mg	60 + 4 Pills	180.59€ 171.99€	Buy
Viagra Generic	50mg	20 Pills	40.52€ 38.59€	Buy
Kamagra Soft Tabs	100mg	32 Pills	120.11€ 114.39€	Buy
Kamagra Oral Jelly	100mg	90 + 8 Sachets	303.56€ 289.10€	Buy
Viagra Generic	100mg	180 + 8 Pills	199.37€ 189.88€	Buy
Kamagra Oral Jelly	100mg	10 Sachets	54.55€ 51.95€	Buy
Viagra Generic	50mg	270 + 8 Pills	198.48€ 189.03€	Buy
Viagra Generic	200mg	10 Pills	40.96€ 39.01€	Buy
Kamagra Soft Tabs	100mg	180 + 8 Pills	425.45€ 405.19€	Buy
Kamagra Oral Jelly	100mg	30 + 5 Sachets	136.20€ 129.71€	Buy
Kamagra	100mg	84 + 6 Pills	264.44€ 251.85€	Buy
Viagra Generic	200mg	360 + 10 Pills	481.98€ 459.03€	Buy
Viagra Generic	100mg	270 + 10 Pills	270.47€ 257.59€	Buy

as eutectic (i.e., melts easily) mixtures, have shown promise [26,27].

Access options

If the primary care physician or urologist is inexperienced or uncomfortable with treating premature ejaculation, early referral to a sex therapist, psychologist, or psychiatrist is indicated. Some physicians are comfortable implementing pharmacologic therapy but not behavioral therapy. As with any medical condition, the patient should be offered all available treatment options, and the physician should proceed with referral for any option considered to require more specialized help than the physician can provide. For men who may have a severe emotional disturbance underlying the premature ejaculation, referral to a mental health professional is most appropriate. Diagnosis and treatment of the various psychological factors that manifest partly as premature ejaculation are beyond the scope of this discussion.

Premature Ejaculation: 2020 Update

Hossein Sadeghi-Nejad, MD, FACS, and Richard Watson, MD, FACS A B S T R A C TIntroduction. Premature ejaculation (PE) is the most common form of male sexual dysfunction. Until very recently, scientific investigation of PE has been hampered by a lack of standardized definitions and objective, validated questionnaires. Small numbers of randomized controlled studies evaluating various treatment options have also added to the challenges facing the clinicians who manage PE. This article provides a summary of some of the more relevant the peer-reviewed literature pertaining to the medical therapy of premature ejaculation.

J Public Health Med

A retrospective review of peer reviewed publications relevant to the field of premature ejaculation and related medical therapies. Review of safety and efficacy of various medical therapies for premature ejaculation. Selective serotonin release inhibitors have been the most promising agents to date. The on-demand “PRN” use of these agents is more convenient, but its efficacy is less well established. Chronic use of this class of medications has been associated with minor, but bothersome side effects. Their application offers a rapid onset of effect, with relatively mild numbness.

Surgical Intervention

More recently, concern over the risk of an increased suicide rate in young men upon initiation of SSRIs has dampened enthusiasm. Recent experience with the use of Tramadol raises the hope that this might prove to be an agent as effective as SSRIs with less worrisome risk of side-effects. New trials on novel formulations of topical solutions are currently underway in the United States. Interest in medical therapy for PE is rapidly increasing and reflected in a disproportionate number of publications in this field in the past few years. Clinical research in this field is hampered by the complexity, variability among sildenafil generic different men and cultures, and subjectivity of PE.

Premature ejaculation: clinical subgroups and etiology

Reliable, appropriately controlled and assessed studies are generally lacking and carefully devised, methodically conducted research is much needed. Sadeghi-Nejad H, and Watson R. Premature ejaculation: Current medical treatment and new directions. Interest in premature ejaculation (PE) has been increasing rapidly among all healthcare professionals. A recent Medline search (January 2008) for articles related to PE, from 1949 to the present, uncovered a total of 589 references of which 160 articles (27%) had been published within the past 2 years.

What you can do in the meantime

Much of this recent surge in interest has focused on new and promising medical relief for men who are troubled by this vexing condition. This review, while recognizing the critical importance of an integrated approach to the evaluation and management of PE—coordinating participation on the part of urologists, mental health professionals, endocrinologists, primary care physicians, and other interested healthcare professionals—is directed primarily at providing an update on recent developments in the medical treatment of PE. The definition of PE is still evolving, but the classic triad involved in the definition includes (i) short intravaginal ejaculatory latency time (IELT), (ii) lack of control, and (iii) sexual dissatisfaction [1]. The World Health Organization (WHO) 1994 International Classification of Diseases defines PE as “an inability to delay ejaculation sufficiently to enjoy lovemaking, manifest as either of the following: occurrence of ejaculation before or very soon after the beginning of intercourse (if a time limit is required: before or within 15 seconds of the beginning of intercourse); occurrence of ejaculation in the absence of sufficient erection to make intercourse possible. The problem is not the result of prolonged absence from sexual activity” [1]. A typically mild adverse side effects profile and availability for on-demand usage are other advantages in this category.

Tip	Explanation	Best Practice
Consult a healthcare professional	To determine appropriateness and safe dosage	Essential before starting treatment
Start with low dose	To minimize side effects and assess response	Usually 25-50 mg
Monitor and report side effects	To optimize treatment and safety	Follow-up appointments
Combine with behavioral therapy	Enhances overall outcomes	Address psychological factors

In 9 of 11 men with PE, prilocaine-lidocaine cream (EMLA [eutectic mixture of local anesthetics], Astra Pharmaceuticals, Wayne, PA, USA) was shown to markedly improve IELT without any reported adverse events [28].

• Premature ejaculation affects about 30% of men.
• Psychological factors often contribute to PE.
• Behavioral therapies can help manage PE.
• Topical anesthetics are alternative treatments for PE.
• SSRI antidepressants are commonly prescribed for PE.
• Combining sildenafil with PE drugs requires care.
• Lifestyle changes like exercise may improve PE.
• Stress and anxiety can trigger premature ejaculation.
• Delay techniques include the stop-start method.
• Medical treatments should be personalized for each patient.
• Education about sexual response can reduce PE.

In phase II testing, topical eutectic mixture for PE (TEMPE), when used as an aerosol 15 minutes

References (14)

The recurrent emerging pattern appears to be that PE is a largely underdiagnosed condition. The etiology of PE has been traditionally divided between “psychogenic” and “biogenic” factors. Psychogenic causes include anxiety, an unpleasant introductory or early sexual experience, infrequent sexual intercourse, poor ejaculatory control techniques, and evolutionary as well as psychodynamic factors. Urologic causes, including chronic prostatitis, have also been implicated [14]. Early animal studies revealed that nonselective agonists of the 5-HT2C receptors delay ejaculation, but selective 5-HT2A agonists do not have a similar effect, and selective 5-HT1A agonists cause a shorter ejaculatory latency compared with 5-HT2C agonists [15,16].

Pregnancy and breastfeeding while taking sildenafil

hypothesized that PE may be secondary to relative hyposensitivity of the 5-HT2C and/or 5-HT1A hypersensitivity [17]. The effect of postsynaptic 5-HT receptor activation on delayed ejaculation was later confirmed by using different selective serotonin reuptake inhibitors (SSRIs) [18–22]. The possible influence of genetic causes was investigated in a survey of 1,196 men in Finland that suggested the presence of a familial or genetic influence in 28% of men [23]. Decreasing sensory perception in the penis has been the goal of most topical agents aimed at treating PE. As a general rule, reliable controlled studies have been lacking in this area. before intercourse, resulted in a 3.8 minute increased in IELT, compared to 0.7 minutes for the placebo.

• Sildenafil enhances blood flow but doesn't directly delay ejaculation.
• PE is often linked with heightened genital sensitivity.
• Timed use of sildenafil may improve sexual confidence.
• Medication dose should be carefully managed.
• PDE5 inhibitors may have a role in PE enhancement.
• Regular sexual activity can help reduce PE symptoms.
• Psycho-sexual therapy addresses underlying issues.
• Identifying triggers can help manage PE episodes.
• Drugs are part of a comprehensive PE management plan.
• Pharmacotherapy may require adjustment over time.
• Always follow medical advice regarding medication use.